Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company MAKO Surgical
With that in mind, let's take a closer look at MAKO's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Fort Lauderdale, Fla. (2004)|
|Market Cap||$1.7 billion|
|Trailing-12-Month Revenue||$84.5 million|
|Management||Chairman/CEO Maurice Ferre
CFO Fritz LaPorte
|Return on Equity (average, past 3 years)||(37.4%)|
|Cash/Debt||$49.8 million / $0|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 861 members who have rated MAKO believe the stock will outperform the S&P 500 going forward.
I think MAKO's [robotic] system has a lot of promise for the ever-aging Boomers, half of whom seem to want to be more active in their twilight years, and the other half who're overweight and putting more pressure on their knees and hips than previous generations. Knee and hip replacements are going to up dramatically in the next decade-plus, and systems like MAKO's will make recovery time much faster than traditional surgeries. I've been concentrating heavily on buying high-and-sustainable yielding companies for my portfolio, so adding MAKO is one of my few pure "growth" plays.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its four-star rating, MAKO may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of MAKO Surgical. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.